melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus, type 1 (HSV-1) encoding granulocyte-macrophage colony stimulating factor (GM-CSF) and is approved for the treatment of melanoma and has shown therapeutic activity in murine tumors known to express high levels of STING.
|
31143509 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.
|
31620131 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
|
31171039 |
2019 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants.
|
30450100 |
2018 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The unique timeline of rh-GM-CSF injections in a melanoma trial, during which yearly MRI scans showed subtle stable demyelination followed by RRMS onset shortly after discontinuation of treatment, may provide some insight on the role of GM-CSF in MS.
|
29414294 |
2018 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Most notably, talimogene laherparepvec (T-VEC), a genetically engineered oncolytic herpesvirus-expressing granulocyte macrophage colony stimulating factor, was recently approved for the treatment of melanoma, representing the first OV to be approved by the FDA as an anticancer therapy in the US.
|
28589085 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
|
28536308 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the development of binding and neutralizing antibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients receiving prolonged therapy with GM-CSF as adjuvant therapy of melanoma and the impact of these antibodies on biological effects.
|
25286079 |
2017 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we constructed a targeted oncolytic vaccinia virus of Tian Tan strain Guang9 (VG9) expressing murine GM-CSF (VG9-GMCSF) and evaluated the antitumor effect of this recombinant vaccinia virus in a murine melanoma model.
|
26803055 |
2016 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated the potency of oncolytic adenovirus Ad5/3-D24-GMCSF on a panel of melanoma cell lines and animal models, and summarized the melanoma-specific human data from the Advanced Therapy Access Program (ATAP).
|
25821063 |
2015 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In an aggressive B16-F10 murine melanoma model, we evaluated the effectiveness and antitumor mechanisms triggered by a surgery adjuvant treatment that combined a local suicide gene therapy (SG) with a subcutaneous genetic vaccine (Vx) composed of B16-F10 cell extracts and lipoplexes carrying the genes of human interleukin-2 and murine granulocyte and macrophage colony stimulating factor.
|
24973616 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine the tumor specificity, cytotoxicity and the antitumor activity of two conditionally replicating oncolytic adenoviruses, SKL001 and SKL002, which expressed granulocyte macrophage colony-stimulating factor (GM-CSF) or anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA4) antibody, respectively, and determine their antitumor efficacy in A549 lung tumor model, B16F10 mouse melanoma tumor model and CMT-64 mouse small lung carcinoma tumor model.
|
25034886 |
2014 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An oncolytic herpes simplex virus engineered to replicate selectively in tumor cells and to express granulocyte-macrophage colony-stimulating factor (GMCSF) was tested as a direct intralesional vaccination in melanoma patients.
|
19915919 |
2010 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adjuvant use of sequential GM-CSF and IL-2 +/- autologous vaccine was well tolerated with good patient compliance and seemed to benefit high-risk patients with surgically resected melanoma.
|
18593361 |
2008 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We report a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for gliomas and melanomas and discuss technical hurdles encountered.
|
16718522 |
2006 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GM-CSF-surface-modified B16.F10 melanoma cell vaccine.
|
16713660 |
2006 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study.
|
12396624 |
2002 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
GM-CSF, IL-12, and B7-2 genes can be transferred to human glioma and melanoma cell cultures efficiently by use of our retroviral vectors.
|
11950413 |
2002 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to determine the safety and antitumor activity of an autologous GM-CSF-secreting melanoma cell vaccine that was engineered ex vivo with recombinant replication-incompetent adenovirus harboring a human GM-CSF gene (Adv/hGM-CSF).
|
11676397 |
2001 |
melanoma
|
0.400 |
Therapeutic
|
disease |
CTD_human |
GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma.
|
11061616 |
2000 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gene gun transfection of human glioma and melanoma cell lines with genes encoding human IL-12 and GM-CSF.
|
10930096 |
2000 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) cDNA in a nonviral expression vector was inserted into MDA-MB-231 (human breast cancer), M21 (human melanoma), B16 (murine melanoma), and P815 (mastocytoma) cells by particle-mediated gene transfer.
|
10078967 |
1999 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
|
10505851 |
1999 |
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have transfected human melanoma cell line 518A2 with the cDNA encoding interleukin-2 (IL-2) or granulocyte-macrophage colony-stimulating factor (GM-CSF), and compared cytokine-producing clones for their ability to induce melanoma-specific cytotoxic T lymphocytes (CTL) from autologous peripheral blood mononuclear cells (PBMC) in vitro.
|
9336741 |
1997 |
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As described in this protocol, fresh human sarcoma and melanoma specimens can be transfected with the GM-CSF DNA-coated gold particles with subsequent production of biologically active GM-CSF protein.
|
9143914 |
1997 |